Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-l-associated myelopathy: A randomised trial

Retrovirology

Volumn 3, Issue , 2006, Pages

  Taylor, Graham P ^a   Goon, Peter ^a   Furukawa, Yoshitaka ^b   Green, Hannah ^c   Barfield, Anna ^a   Mosley, Angelina ^a   Nose, Hirohisa ^b   Babiker, Abdel ^c   Rudge, Peter ^d   Usuku, Koichiro ^b   Osame, Mitsuhiro ^b   Bangham, Charles R M ^a   Weber, Jonathan N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; LAMIVUDINE; PLACEBO; ZIDOVUDINE;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; LETHARGY; LYMPHOCYTE COUNT; MALE; NERVE INJURY; NONHUMAN; PARESTHESIA; PERIPHERAL BLOOD MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD INFECTION; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS STRAIN;

AGED; ANTI-HIV AGENTS; CELL PROLIFERATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PARAPARESIS, TROPICAL SPASTIC; PLACEBOS; VIRAL LOAD; ZIDOVUDINE;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 33749641639     PISSN: 17424690     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-3-63     Document Type: Article

References (34)

1. Gallo RC: The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology 2005, 2:.
2. Takatsuki K: Discovery of adult T-cell leukemia. Retrovirology 2005, 2:.
3. Gessain A. Vernant JC, Maurs L, Barin F, Gout O, Calender A, de The G: Antibodies to human T-lymphotropic virus type-1 in patients with tropical spastic paraparesis. Lancet 1985, ii:407-409.
4. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M: HTLV-1 associated myelopathy, a new clinical entity (letter). Lancet 1986, i: 1031-1032.
5. Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y, Khabbaz RF, Janssen RS: The risk of development of HTLV-1 associated myelopathy/ tropical spastic paraparesis, among persons infected with HTLV-1. J Aquir Immun Defic Synd 1990, 3:1096-1101
6. Tosswill JHC, Taylor GP, Tedder RS, Mortimer PP: HTLV-1-associated disease in England and Wales 1993-7:A retrospective study of serology requests. BMJ 1999, 320:611-612.
7. Yoshida M, Osame M, Kawai H, Toita M, Kuwasaki N, Nishida Y, Hiraki Y, Takahashi K, Nomura K, Sonoda S, Eiraku N, Ijichi S, Usuku K: Increased replication of HTLV-1 in HTLV-1-associated myelopathy. Ann Neurol 1989, 26:331-335.
8. Tosswill JHC, Taylor GP, Clewley JP, Weber JN: Quantification of proviral DNA load in human T-cell leukaemia virus type-1 infections. J Virol Methods 1998, 75:21-26.
9. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CRM, Izumo S, Osame M: Analysis of HTLV-1 proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998, 4:586-593.
10. Cartier L, Cea JG, Vergara C, Araya F, Born P: Clinical and neuropathological study of six patients with spastic paraparesis associated with HTLV-1: an axomyelinic degeneration of the central nervous system. J Neuropathol and Experimental Neurology 1997, 56-403-413.
11. Iwasaki Y, Ohara Y, Kobayashi I, Akizuki S: Infiltration of helper/ inducer T lymphocytes heralds central nervous system damage in human T-cell leukemia virus infection. Am J Pathol 1992, 140:1003-1008.
12. Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffe ES, Leist TP, Pardoll DM, Jacobson S, Schneck JP: Direct visualization of antigen-specific T cells: HTLV-1 Tax 11-19-specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci USA 1998, 95:7568-7573.
13. Biddison WE, Kuboto R, Kawanishi T, Taub DD, Cruikshank WW, Center DM, Connor EW, Utz U, Jacobson S: Human T cell leukaemia type 1 (HTLV-1)-specific CD8+ CTL clones from patients with HTLV-1-associated neurological disease secrete proinflammatory cytokines, chemokines and matrix metalloproteinase. J Immunol 2002, 159:2018-2025.
14. Goon PKC, Hanon E, Igakura T, Tanaka Y, Weber JN, Taylor GP, Bangham CRM: High frequencies of Th1-type CD4+ T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV1-associated myelopathy/tropical spastic paraparesis. Blood 2002, 99:3335-3341.
15. Osame M, Igata A, Matsumoto M, Kohka M, Usuku K, Izumo S: HTLV-1-associated myelopathy (HAM): Treatment trials, retrospective survey and clinical and laboratory findings. Hematology Reviews 1990, 3:271-284.
16. Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, Araki S, Mori M, Nagataki S, Matsukura S, Akamine T, Nakagawa M, Yamamoto I, Osame M: Interferon-alpha is effective in HTLV-1-associated myelopathy: a multicenter, randomized, doubleblind, controlled trial. Neurology 1996, 46:1016-1021.
17. Matsushita S, Mitsuya H, Reitz MS, Broder S: Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type 1. J Clin Investig 1987, 80:394-400.
18. Macchi B, Faraoni I, Zhang J, Grelli S, Favalli C, Mastino A, Bonmassar E: AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type 1 to adult peripheral blood mononuclear cells in vitro. J Gen Virol 1997, 78:1007-1016.
19. Isono T, Ogawa K, Seto A: Antiviral effect of zidovudine in the experimental model of adult T-cell leukaemia in rabbits. Leukaemia Research 1990, 14:841-847.
20. Gout O, Gessain A, Iba-Zizen M, Kouzan S, Bolgert F, de The G, Lyon-Caen O: The effect of zidovudine on chronic myelopathy associated with HTLV-1. J Neurol 1991, 238:108-109.
21. Sheremata WA, Benedict BS, Squilacote DC, Sazant A. de Freitas E: High-dose Zidovudine induction in HTLV-1 associated myelopathy: Safety and possible efficacy. Neurology 1993, 43:2125-2129.
22. Taylor GP, Hall SE, Navarette S, Michie CA, Davis R, Witkover AD, Rossor M, Nowak MA, Rudge P, Matutes E, Bangham CRM, Weber JN: Effect of Lamivudine on human T-cell leukaemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-Tax cytotoxic T-cell frequency in patients with HTLV-1 associated myelopathy. J Virol 1999, 73:10289-10295.
23. Dougan S, Payne LJC, Tosswill JHC, Davison K, Evans BG: HTLV infection in England and Wales in 2002 - results from an enhanced national surveillance system. Commun Dis Public Health 2004, 7:207-211.
24. Balestrieri E, Forte G, Matteucci C, Mastino A, Macchi B: Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrobial Agents Chemotherapy 2002, 46:3080-3083.
25. Garcia-Lerma JG, Nidtha S, Heneine W: Susceptibility of Human T Cell Leukaemia Virus Type 1 to Reverse-transcriptase inhibitors: evidence of resistance to lamivudine. J Infect Dis 2001, 184:507-510.
26. Toro C, Rodés B, Mendoza Cd C, Soriano V: Lamivudine resistance in human T-cell leukaemia virus type 1 may be due to a polymorphism at codon 118 (V →I) of the reverse transcriptase. Antimicrobial Agents Chemotherapy 2003, 47:1774-1775.
27. Derse D, Hill SA, Lloyd PA, Chung HK, Morse BA: Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. J Virol 2001, 75:8461-8468.
28. Lau AW, Nightingale S, Taylor GP, Gant T, A. C: Enhanced MDRI Gene Expression in Human T-cell Leukaemia Virus-1-infected patients offers new prospects for therapy. Blood 1998, 91:2467-2474.
29. Bangham CRM: The immune response to HTLV-1. Curr Opin Immun 2000, 12:397-402.
30. Igakura T, Stinchcombe JC, Goon PKC, Taylor GP, Weber JN, Griffiths GM, Tanaka Y, Osame M, Bangham CRM: Spread of HTLV-1 Between Lymphocytes by Virus-induced Polarization of the Cytoskeleton. Science 2003, 299:1713.
31. http://www.rcc.tech-res.com/. 2006.
32. Organisation WH: WHO diagnostic guidelines of HAM. Weekly Epidemiological Record 1989, 49:382-383.
33. Goon PKC, Igakura T, Hanon E, Mosley AJ, Barfield A, Barnard AL, Kaftantzi L, Taylor GP, Weber JN, Bangham CRM: HTLV-1 specific CD4+ T cells: Immunodominance hierarchy and preferential infection with HTLV-1. J Immunol 2004, 172:1735-1743.
34. Hanon E, Goon P, Taylor GP, Hasegawa H, Tanaka Y, Weber JN, Bangham CRM: High production of interferon-g but not interleukin-2 by human T cell lymphotropic virus type 1 (HTLV-1) - infected peripheral blood mononuclear cells. Blood 2001 98:721-726.